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Abstract
Background: Major depression and type 2 diabetes often co-occur. Novel treatment strategies for depression in
type 2 diabetes patients are warranted, as depression in type 2 diabetes patients is associated with poor prognosis
and treatment results. Major depression and concurrent sleep disorders have been related to disturbances of the
biological clock. The biological clock is also involved in regulation of glucose metabolism by modulating peripheral
insulin sensitivity. Light therapy has been shown to be an effective antidepressant that ‘resets’ the biological clock.
We here describe the protocol of a study that evaluates the hypothesis that light therapy improves mood as well as
insulin sensitivity in patients with a major depressive episode and type 2 diabetes.
Methods/design: This study is a randomised, double-blind, parallel-arm trial in 98 participants with type 2 diabetes
and a major depressive episode, according to DSM-IV criteria. We will assess whether light therapy improves
depressive symptoms and insulin sensitivity, our primary outcome measures, and additionally investigate whether
these effects are mediated by restoration of the circadian rhythmicity, as measured by sleep and hypothalamic-pituitary-
adrenal axis activity. Participants will be randomly allocated to a bright white-yellowish light condition or dim green light
condition. Participants will undergo light therapy for half an hour every morning for 4 weeks at home. At several time
points, namely before the start of light therapy, during light therapy, after completion of 4 weeks of light therapy and
after 4 weeks follow-up, several psychometrical, psychophysiological and glucometabolic measures will be performed.
Discussion: If light therapy effectively improves mood and insulin sensitivity in type 2 diabetes patients with a major
depressive episode, light therapy may be a valuable patient friendly addition to the currently available treatment
strategies. Additionally, if our data support the role of restoration of circadian rhythmicity, such an observation may
guide further development of chronobiological treatment strategies in this patient population.
Trial registration: The Netherlands Trial Register (NTR) NTR4942. Registered 13 January 2015.
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Background
Major depression is a mood state characterised by de-
pressed mood and loss of interest or pleasure for at least
2 weeks, together with several other symptoms, such as
loss of energy, diminished ability to concentrate, changes
in appetite or physical activity and sleep disturbances.
Up to 20 % of the type 2 diabetes (T2D) patients suffer
from major depression [1], where depression appears to
be more persistent and recurrent [2–4] and has adverse
effects on health behaviour and treatment adherence
[5, 6]. Consequently, depression in T2D patients is asso-
ciated with an increased risk for diabetes complications
and mortality [7–16], as well as an economic burden to
society [17, 18]. Hence, adequate treatment of depres-
sion in T2D patients is required.
Major depression in T2D patients can be treated by
psychotherapy or antidepressant drugs. Meta-analytic
evidence has shown that antidepressant treatments, both
psychological and pharmacological, are only moderately
effective in the reduction of depressive symptoms in
T2D patients [19, 20]. Glycaemic improvements from
anti-depressant therapies have been very modest [20] and
some antidepressant drugs have even shown negative
metabolic effects, such as weight gain [21] and glucose
dysregulation [22]. There clearly is a need for more effica-
cious treatment strategies of major depression in T2D
patients, which improve both psychiatric symptoms and
glycaemic control [23].
Light therapy has been shown to be a patient friendly,
non-pharmacological antidepressant, which has an early
onset of action and a mild adverse-effect profile [24]. Light
therapy has been proven successful in patient groups that
are traditionally difficult to treat, such as patients with
chronic depression and postpartum depression [25–27],
and may therefore be effective in the treatment of major
depression in T2D patients. Restoration of the circadian
rhythmicity, which is often disrupted in depression, has
been assumed to be the mechanism of action of light ther-
apy [28]. The biological mechanism behind this chronobi-
ological effect is that light induces the specialised light
sensitive retinal ganglion cells to release glutamate in the
suprachiasmatic nucleus (SCN) of the brain, which is
often called the ‘biological clock’ [29]. The SCN is in-
volved in the regulation of melatonin release, activation of
the hypothalamic-pituitary-adrenal (HPA) axis as well as
regulation of sleep-wake patterns. A recent clinical study
in elderly patients with non-seasonal depression showed
that light therapy improved mood, increased upslope
evening melatonin levels, attenuated cortisol release and
enhanced sleep efficiency [30]. The SCN is also involved
in regulation of glucose metabolism [31], which suggests
that light therapy may affect glucose metabolism. Two
case reports on the effect of light therapy in patients with
seasonal depression and insulin dependent diabetes
support the idea of effects of light therapy on glucose
metabolism [32, 33].
Sleep disturbances, which are indicative of disturbed
circadian rhythmicity, often co-occur with major depres-
sion [34] and have been associated with hyperglycaemia
and increased rates of incident diabetes [35]. In patients
with T2D, sleep disorders are associated with a 23 %
higher fasting glucose level, a 48 % increment in fasting
insulin levels and a decreased insulin sensitivity as indi-
cated by a 82 % increase in homeostatic model assessment
of insulin resistance (HOMA-IR) [36, 37]. Two studies
using a hyperinsulinaemic-euglycaemic clamp procedure,
which is considered the gold standard for the quantifica-
tion of whole-body insulin sensitivity, observed strong ef-
fects of one single night of sleep restriction on insulin
sensitivity in healthy volunteers [38] and in patients with
type 1 diabetes [39]. Whether the reversed situation, im-
proved insulin sensitivity, can be reached after restoration
of the circadian rhythmicity in patients with sleep distur-
bances has, to the best of our knowledge, not been tested.
We believe that light therapy may be a promising treat-
ment option for patients with major depression and T2D,
as light therapy may result in concurrent improvements in
depressive symptoms and insulin sensitivity through restor-
ation of the circadian rhythmicity (Fig. 1). To substantiate
this theory, we aim to perform a randomised, double-
blind, parallel-arm trial that investigates the following
hypotheses:
1. Light therapy improves depressive symptoms in
patients with a major depressive episode and T2D.
2. Light therapy improves insulin sensitivity in patients
with a major depressive episode and T2D.
3. Effects of light therapy on depressive symptoms and
insulin sensitivity are mediated by restoration of the
circadian rhythmicity, as measured by the sleep-wake
pattern and HPA axis activity.
If light therapy proves to be an effective antidepressant
in T2D patients and improves insulin sensitivity, light
therapy may be a valuable addition to the currently avail-
able treatment options for major depression in T2D
patients, assuming that improvements in insulin sensitiv-




This study entails a randomised, double-blind, parallel-
arm trial, consisting of a run-in period of at least 1 week
to allow for study effects, a four-week intervention
period and a four-week follow-up period. Assessments
of primary and secondary outcome measures, as well as
mediating factors, will be performed at baseline, during
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the intervention, after the intervention and after the
follow-up period to assess direct and long-term effects
of light therapy. The trial methods reporting is consist-
ent with the CONSORT statement [40]. A schematic
overview of the trial protocol is provided in Fig. 2.
Approval
This study will be executed in accordance with the Helsinki
Declaration [41]. Participation in the study is voluntary and
written informed consent is obtained. Participants can
withdraw their consent to participation at any time, without
specification of reasons. The ethical committee of the VU
University Medical Centre, Amsterdam, The Netherlands,
approved this study.
Participants
Participants will be recruited using a number of strategies:
(1) Participants of previous research studies of the VU
University Medical Centre will be informed about the
study; (2) patients will be informed about the study by
affiliated health-care-workers; (3) advertisements in local
newspapers, folders and posters in waiting rooms of
affiliated health-care-institutions; and (4) via our website.
In case patients are interested in participation, a screening
consisting of three questions will be applied by telephone.
Only patients without a history of laser photocoagulation
for the treatment of diabetic retinopathy and scoring 2 or
more on one or both questions of the Patient Health
Questionnaire-2, a screening tool for a major depressive
episode [42], will be invited for a screening visit.
Eligibility for participation will be determined during a
screening visit, which constitutes a standardised psychiatric
interview, as assessed with the Composite International
Diagnostic Interview (CIDI) WHO version 2.1 [43], a med-
ical interview on disease history and medication, physical
and blood examination, visual acuity test and fundus
photography.
Inclusion criteria
Participants will be included when (1) 18 years or older;
(2) having a documented physician-based diagnosis of
T2D; and (3) having a major depressive episode according
to DSM-IV criteria.
Disrupted biological clock:
- Disrupted sleep-wake pattern





Restoration of the biological 
clock:
- Improved sleep-wake pattern









Fig. 1 Research hypothesis. Schematic overview of the research hypothesis. a Schematic overview of the relationship between the biological clock, depressive
symptoms and insulin sensitivity in patients with major depression and type 2 diabetes. b Schematic overview of the hypothesised effect of light therapy on
the biological clock, depressive symptoms and insulin sensitivity in patients with major depression and type 2 diabetes
S T0 T4 T8
4 weeks 4 weeks
Bright white-yellowish light (N=49)
Dim green light (N=49)
Fig. 2 Study protocol. Schematic overview of the study protocol. Abbreviations: S screening, T0 start of the intervention, T4 4 weeks relative to the
start of the intervention, T8 8 weeks relative to the start of the intervention
Brouwer et al. BMC Psychiatry  (2015) 15:169 Page 3 of 10
Exclusion criteria
Participants will be excluded from participation when
any of the following criteria is present: (1) a recent his-
tory of or current use of light therapy; (2) shift worker;
(3) a recent change in antidepressant or blood-glucose
lowering medication or therapy (e.g. psychotherapy); (4)
use of oral glucocorticoids, melatonin, or cytostatics; (5)
pregnancy; (6) psychosis, mania, (probable) dementia,
severe drug or alcohol abuse, delirium, and severe acute
suicidality; (7) a history of light-induced migraine or epi-
lepsy or severe side effects to light therapy in the past; (8)
visual acuity <60 %, diabetic retinopathy EURODIAB
grades 3, 4 or 5 (severe non-proliferative or preproliferative
retinopathy, photocoagulated retinopathy, proliferative
retinopathy) [44, 45], senile macula degeneration; (9) other
medical condition or recent medical event that potentially
compromises the effects or safety of light therapy.
There are no restrictions with respect to type of anti-
depressant or blood-glucose lowering medication.
Safety
Light therapy has proven to be a patient friendly and
safe intervention, with little side effects that normally
resolve after discontinuation of the therapy.
The ocular safety of light therapy, however, remains
matter of debate. Follow-up of patients with cumula-
tive exposure durations up to 1250 h demonstrated
that light therapy is safe in patients without pre-
existing ocular abnormalities [46]. Ocular effects of
light therapy in patients with pre-existing ocular ab-
normalities, diabetes, or in patients using photosensi-
tising medication, however, remain under speculation
[47]. Therefore, stringent ocular exclusion criteria
have been defined (e.g. diabetic retinopathy EURO-
DIAB grade 3, 4 and 5) and safety precautions have
been taken, such as the use of filters that eliminate
an additional part of the energetic light spectrum
below 450 nm (blue light), which theoretically has the
most damaging potential, in addition to the of UV-A
and UV-B filters with which the light therapy lamps
are normally equipped with (Fig. 3).
Mania (in bipolar depressive patients) and acute sui-
cidality have been theorised as potential psychiatric side
effects of light therapy [24, 48, 49] although there is lit-
tle documented evidence. The investigator will contact
a participant weekly during the intervention in order to


























Fig. 3 Light spectral and relative intensity measures. Light spectral and relative intensity measures at 50 cm distance of the bright white-yellowish
light condition (yellow), the dim green light condition (green) and the lamp without filter (blue)
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Intervention
The intervention will consist of light therapy for 30 min
every morning, for four consecutive weeks at home. The
time at which light therapy is applied in the morning
will be determined according to results from the
Morningness-Eveningness Questionnaire [24] to allow
for accurate phase timing, but in agreement with the
participant, to make sure the light therapy can be incor-
porated in the participant’s daily rhythm. A timer will be
installed to provide a 90 min time window in which the
participants can follow the 30 min of light therapy. This
provides the participants with a time window of an hour
to start the light therapy, which will prevent participants
from taking light therapy at another time of the day. Par-
ticipants will sit in front of the light boxes at a distance
of 50 cm and at an angle of 45 °, while they eat breakfast
or do some reading (protocol as recommended by Wirz-
Justice and colleagues, 2009 [50]).
Diamond-5 SAD lightbox (CE certified; SAD Lightbox
Company, Berkshire, United Kingdom) light therapy
lamps will be used. The lamps will be equipped with
heat-resistant filters, to create an experimental and pla-
cebo light therapy condition.
The experimental condition will be bright white-
yellowish light, with an intensity of 10.000 lx at a distance
of 50 cm. The lamps will be equipped with high-
throughput pale yellow filters (LCT Yellow, Model 212;
Lee Filters, Burbank, California, United States of Amer-
ica), to filter the spectrum below 450 nm for ocular safety.
The circadian system appears most sensitive to light with
short wavelengths and light therapy with light of around
470 nm is able to induce a substantial phase advance [51].
We therefore think filtering for ocular safety will not inter-
fere with our hypothesis. Spectral and intensity measures
are depicted in Fig. 3.
The control condition will be dim green light with an
intensity of 450 lx at a distance of 50 cm. As the green
part of the spectrum around 545 nm is biologically rela-
tively inactive [51], we expect there to be no substantial
effects, especially at this low intensity, although expecta-
tions will be quite comparable to white light, as was pre-
viously shown for dim red light [52]. To create the dim
green light condition the lamps will be equipped with
low-throughput dark green filters (Aurora Borealis Green:
Model 740; Lee Filters, Burbank, California, United States
of America). Spectral and intensity measures are depicted
in Fig. 3.
Compliance
Participants will be instructed by research assistants on
how to follow the light therapy program. The position of
the light therapy lamp and the participant during light
therapy will be marked, so the participant can retake the
same position day after day. The investigator will contact
the participants weekly during the intervention period
and compliance will be monitored and reinforced when
needed.
Randomisation
Participants will be randomly assigned to the experimental
or placebo condition at a 1:1 ratio. Randomisation will be
performed in blocks of 6 using a computer-generated
table and will be stratified for whether a participant will or
will not take part in the hyperinsulinaemic-euglycaemic
clamp experiment, which will only be performed in a sub-
group of the participants.
Blinding
Both investigators and participants will be blind with
respect to the treatment conditions. Participants will be
informed that two different colours of light (white-
yellowish and green) will be compared, but not that a
placebo condition is present, nor that the green light is
less bright or less effective compared to the white-
yellowish lamp. This approach is effective in avoiding
differences in participants’ expectations regarding the ef-
fectiveness of the conditions, as expectations may affect
treatment effects [30, 53, 54]. The investigators involved
in data acquisition will be blind to the conditions, as the
lamps will be delivered at the participants’ homes by in-
dependent research assistants, who are instructed not to
discuss the brightness of the lamp, and participants will
be instructed not refer any details of their condition to
the investigators. A similar blinding procedure showed
to be successful in a previous study conducted by our
institute [30].
To evaluate the blinding procedure, participants’ expec-
tations of the effect of light therapy on depressive symp-
toms will be measured before installation of the light
therapy lamps, using an adapted version of the expecta-
tions questionnaire developed by Lieverse and colleagues,
2011 [30].
Study setting
Test visits will be carried out at clinical research units of
two locations of the VU University Medical Centre:
Amsterdam and Hoorn, The Netherlands.
Outcome measures
Outcome measures will be evaluated just before the start
of the intervention (T0), after 4 weeks of light therapy
(T4) and after 4 weeks of follow-up (T8). Changes in out-
come measures (T0 – T4, T4 – T8, or T0 – T8) will be
compared between the two study conditions. Additionally,
several outcome measures will also be evaluated weekly
during the intervention period (T0, T1, T2, T3, T4, T8) to
allow for analysis or temporal changes in these measures.
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A schematic overview of the outcome measures is
depicted in Table 1.
Participant characteristics
Various participant characteristics will be obtained
before the start of the light therapy (S, T0): psychiatric
diagnosis in the category of mood and anxiety disorders
according to DSM-IV criteria as assessed using the CIDI
WHO version 2.1 [43]; seasonality of depression [55];
chronotype [24]; presence of sleep apnoea [56]; medical
history; current medication; biochemical blood tests; and
sociodemographic factors. These participant characteris-
tics allow for the characterisation of our study sample.
Primary outcome measures
Depressive symptoms will be assessed by the self-report
version of the Inventory of Depressive Symptomatology
(IDS) (T0, T1, T2, T3, T4, T8) [57]. The IDS allows for
profiling of depression, as the questionnaire discriminates
directions of the weight, appetite, sleep and psychomotor
symptoms, and can be used to determine depression se-
verity. Scores between 14 and 25 indicate mild depression;
scores between 26 and 38 indicate moderate depression;
scores between 39 and 48 indicate moderate to severe de-
pression; and scores of 49 and greater indicate severe de-
pression. A reduction of 50 % or greater of the baseline
depression score is regarded as a clinically significant re-
duction in depressive symptoms. Depression remission is
a priori defined as an IDS score of 13 or less.
Insulin sensitivity will be evaluated at the baseline visit
(T0) and the visit following light therapy (T4) in a sub-
sample of 60 participants. Insulin sensitivity will be
quantified using a hyperinsulinaemic-euglycaemic clamp
procedure, the gold standard for the quantification of
whole-body insulin sensitivity. This procedure quantifies
the rate of exogenous glucose infusion required to
Table 1 Outcome measures
Weeks relative to start intervention (T) 0 1 2 3 4 5 6 7 8
Visits S 1 2 3
Telephone contact 1 2 3 4
Run-in phase X-es X-es
Intervention phase X-es X-es X-es X-es




chronotype, sleep apnoea, medical history,




Psychometrical measures Depressive symptoms X X X X X X
Anxiety symptoms X X X X X X
Diabetes-related distress X X X
Quality of life, disability X X X
Glucometabolic measures Insulin sensitivity X X
HbA1c level X X X
Fasting glucose level X X X
Hypoglycaemic events X X X X X X
Circadian mediating factors Diurnal HPA axis activity X X X
Objective sleep X X X
Subjective sleep X X X X X X
Other factors Body weight, body mass index,
waist-hip ratio, body composition
X X X
Physical activity X X X
Autonomic nervous system function X X X
Safety Adverse effects X X X X X X
Ophthalmological examination X X
Compliance Participant-report compliance X X X X
Light meter X X X
Abbreviations: S screening, HPA hypothalamic-pituitary-adrenal
Brouwer et al. BMC Psychiatry  (2015) 15:169 Page 6 of 10
maintain the plasma glucose concentration at euglycae-
mic levels in response to a fixed increase in the plasma
insulin level. Because 80–90 % of the infused glucose is
taken up by skeletal muscle under conditions of euglycae-
mic hyperinsulinaemia, insulin sensitivity measured with
this procedure primarily reflects that of skeletal muscle
[58]. The hyperinsulinaemic-euglycaemic clamp proced-
ure is performed as previously described by DeFronzo and
colleagues [59]. Briefly, participants will be admitted at
our research unit following an overnight fast. They are
placed in a semi recumbent position during the proced-
ure. A cannula will be inserted into a vein in the antecubi-
tal fossa for infusion of glucose and insulin. Insulin
(Novorapid 100 IU/ml; Novo Nordisk, Bagsvaerd,
Denmark) will be continuously infused at a rate of
40 mU/m2*min, which creates a hyperinsulinaemic state,
which will largely decrease endogenous glucose produc-
tion by the liver. A contralateral dorsal hand or wrist vein
will be cannulated and maintained at 50 °C to permit sam-
pling of arterialised venous blood for bedside measure-
ment of blood glucose concentrations (Yellow Springs
Instrument 2300 STAT Analyser, Yellow Springs, Ohio,
Unites States of America) every 5 min. Glucose (20 %) will
be infused at a variable rate to maintain blood glucose
levels at 5 mmol/L. When a stable blood glucose level of
5 mmol/L is achieved (minimally after 90 min of insulin
infusion), the blood glucose level will be kept at this level
for 30 min (steady state). At this point the glucose infu-
sion rate equals the skeletal muscle glucose uptake. The
M-value (expressed as the amount of glucose infusion in
mol/kg*min) will be calculated over this steady state
period as described previously [59]. Blood samples for
measurement of plasma insulin concentrations will be ob-
tained at several time points before and during insulin
infusion.
Secondary outcome measures
Secondary participant-reported outcome measures
include anxiety symptoms, as anxiety symptoms often
co-occur with depressive symptoms; diabetes-related dis-
tress; and quality of life and disability, as these measures
are increasingly important when evaluating new treat-
ments in clinical trials. Anxiety symptoms are evaluated
using the Beck Anxiety Inventory (T0, T1, T2, T3, T4,
T8) [60], diabetes-related distress is measured using the
Problem Areas In Diabetes questionnaire (T0, T4, T8)
[61], quality of life using the EuroQol-5 Dimensions
questionnaire (T0, T4, T8) [62] and disability using the
Sheehan Disability Scale (T0, T4, T8) [63].
Glucometabolic secondary outcome measures will in-
clude the clinically relevant glycated haemoglobin A1c
(HbA1c) level (T0, T4, T8), fasting plasma glucose level
(T0, T4, T8), and number of hypoglycaemic events as
reported in the diary (T0, T1, T2, T3, T4, T8).
Circadian mediating factors
Mediating factors that reflect circadian rhythmicity will
include diurnal HPA axis activity, objective accelerom-
eter measures of sleep duration and subjective measures
of sleep duration and quality.
Diurnal HPA-axis activity is assessed by free cortisol
assessment using six saliva samples per day (T0, T4, T8).
The morning cortisol awakening responses will be
assessed by four saliva samples in the morning: after
awakening, plus 30 min, plus 45 min and plus 60 min.
Cortisol levels in the evening will be obtained from two
saliva samples in the evening at 10 and 11 pm. Saliva
samples will be collected at home, using cotton swaps
(Salivette, Sarstedt, Nümbrecht, Germany) that will be
stored in the refrigerator. Participants will bring the
samples with them to the research facility where the sal-
iva will be centrifuged and stored at −80 °C for analysis.
Objective measures of sleep will be obtained using a
microelectromechanical system (GENEActiv, Activein-
sights Ltd, Kimbolton, United Kingdom), an accelerom-
eter that can reliably measure sleep-wake behaviour [64]
and will be worn for one week continuously. Estimates
of sleep parameters will be obtained from these data
using a previously validated algorithm [64].
Subjective sleep parameters will be scored using the
Pittsburg Sleep Quality Index (T0, T4, T8) [65], the
Insomnia Severity Index (T0, T2, T4, T8) [66, 67] and a
sleep diary (T0, T1, T2, T3, T4, T8) [68].
Other factors
Other potential mediating or confounding factors include
body weight, body mass index, waist-hip ratio, body com-
position, physical activity and autonomic nervous system
function. Body composition will be measured by bioelec-
trical impedance analysis (T0, T4, T8), physical activity
will be measured using a wrist-worn accelerometer (T0,
T4, T8) and autonomic nervous system function will be
evaluated with spectral analysis of the heart rate variability
(T0, T4, T8). Whole blood (T0, T4), plasma and serum
(T0, T4, T8) will be collected and stored for future add-
itional research questions that require additional biochem-
ical or DNA analyses.
Safety and tolerability of light therapy
Adverse effects of light therapy will be assessed, using a
self-report adverse effects questionnaire (T0, T1, T2, T3,
T4, T8) that is based on the side effect interview from
Lieverse and colleagues, 2011 [30, 69]. The following
items will be assessed: tired eyes, dry eyes, painful eyes,
visual impairment, headache, early morning awakening,
fatigue, drowsiness, weakness, nervousness, anxiety, agita-
tion, irritability, dizziness, nasal congestion, fever, seating,
hypoglycaemia, hot flushes, allergy, rash, cough, dry
mouth, nausea, vomiting, decreased appetite, increased
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appetite, constipation and diarrhoea. Presence and severity
of each item will be rated as absent, mild, moderate or
severe.
Additionally, we will assess ophthalmological effects,
by measures of visual acuity, contrast sensitivity and
fundus photography. An ophthalmologist will perform
grading of the photographs according to the EURODIAB
study grading system [5, 44, 45].
Compliance
Participants will note their compliance to therapy in a
diary. Objective measures of compliance will be obtained
from lux-meters built in a wrist-worn accelerometer.
Sample size
A previous study on the effects of light therapy on depres-
sion in elderly patients using a comparable protocol [30]
showed that direct treatment effects of light therapy on
depressive symptoms were moderate (effect size 0.50
Cohen’s d), and increased during follow-up (effect size
0.91 Cohen’s d), with one-sided testing. Power calculations
were based on the expected moderate effect size and a
conservative repeated measures correlation of 0.6, using
conventional values for α (0.05) and β (0.20), and two-
tailed tests with equal groups – the sample size aimed for
will be 42 participants per treatment arm. Accounting for
an attrition rate of 15 %, we derive at a total sample size of
98 participants.
The question whether light therapy alters insulin sensi-
tivity in type 2 diabetes patients with depression will be
tested in a subsample of 60 participants in total. A sample
size of 30 participants per treatment arm is sufficient to
detect a moderate effect (0.76 Cohen’s d) of light therapy
on insulin sensitivity, with conventional values for α (0.05)
and β (0.20), and two-tailed tests with equal groups, as-
suming a dropout rate of 10 %. The hyperinsulinaemic-
euglycaemic clamp experiment will thus be performed in
a subgroup of the participants and participation in this
procedure will be optional. Participants with difficult ven-
ous access or medical conditions that impair the safety of
the procedure will be excluded from participation in the
hyperinsulinaemic-euglycaemic clamp experiment.
Statistical analyses
Data will be analysed using SPSS (version to be deter-
mined). Participant and baseline characteristics across
treatment groups will be compared using analysis of vari-
ance (ANOVA) and chi-squared statistics. Analyses of our
primary outcome measures will be performed on the basis
of intention to treat. The superiority of the bright white-
yellowish light condition compared to dim green light
condition will be tested using a repeated measures mixed
models design. Both treatment (independent of time) and
condition*time interaction effects will be evaluated.
Repeated measures logistic regression will be applied to
test differences in depression remission rates. Preacher
and Hayes mediation analysis will be performed to test
whether the effects of light therapy are mediated by res-
toration of the circadian rhythmicity. Post hoc analyses of
this study may include subgroup or discriminant analysis
to test if participant characteristics can be identified that
predict positive effects of light therapy, such as baseline
depression severity, baseline depressive symptoms profile,
baseline insulin sensitivity, baseline HbA1c, chronotype,
or baseline insomnia severity, seasonality of depression
and time of year at which the participant was included in
the study.
Discussion
To the best of our knowledge, we are the first to investi-
gate the effects of light therapy on depressive symptoms
and insulin sensitivity in T2D patients with a major
depressive episode.
Creating a valid placebo condition is a major challenge
in light therapy trials, due to the visibility of light. In previ-
ous research various placebo conditions have been used:
deactivated air ionisation generators, dim red light placebo
conditions, dim white light conditions and inappropriate
timing of light therapy [30]. We however decided to use a
dim green light condition as placebo for several reasons.
Firstly, inappropriate timing of light therapy can be diffi-
cult, as phase alterations vary in non-seasonal depression.
Secondly, we regard a dim white light condition less cred-
ible when compared to a coloured dim light condition, as
a coloured glare to the surroundings is absent for a white
light condition. Thirdly, a dim red light placebo condition
may be less credible nowadays, as much more information
on (e.g. on the active spectrum of light) has become avail-
able to the public. We considered dim green light a valid
placebo condition, reasoning that because the green part
of the spectrum around 545 nm is biologically relatively
inactive [51], at low intensities there will be no substantial
effect, while dim green light will induce positive expecta-
tions quite comparable to white light, as was previously
shown for dim red light [52].
Participation in the hyperinsulinaemic-euglycaemic clamp
experiment is optional, to prevent participants to refrain
from participation in our study. This procedure may intro-
duce a selection bias, with potentially psychiatrically and
somatically less severely affected participants in the
hyperinsulinaemic-euglycaemic clamp subgroup, limiting
the generalizability of our findings on insulin sensitivity.
Participants with diabetic retinopathy EURODIAB grade
3–5 will be excluded from participation in this study as a
safety precaution. If our study does find positive effects on
mood and insulin sensitivity in absence of ocular damage,
it may be worthwhile to investigate the effects of light
therapy in patients with diabetic retinopathy EURODIAB
Brouwer et al. BMC Psychiatry  (2015) 15:169 Page 8 of 10
grade 3–5, as these patients are expected to have a greater
risk for depression and poor glycaemic control.
Conclusions
If light therapy shows to be safe and effective in the reduc-
tion of depressive symptoms and improves insulin sensi-
tivity, light therapy may be a valuable patient friendly
addition to the currently available treatment strategies for
major depression in T2D patients, assuming that im-
proved insulin sensitivity may lead to improvements in
glycaemic control, as measured by fasting glucose levels
and HbA1c levels. Additionally, if our data support the
role of restoration of circadian rhythmicity in these effects,
such a finding may guide further development of chrono-
biological treatment strategies in these patients, as well as
provide a basis for research into the effects of light therapy
in other T2D patients, such as those without major
depression but with sleep disorders.
Trial status
The first participant was enrolled in June 2014. At the
time of submission of this study protocol participants
were still being recruited.
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